Kronos Bio Inc. (KRON) News

Kronos Bio Inc. (KRON): $0.90

0.03 (+3.28%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add KRON to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#33 of 329

in industry

Filter KRON News Items

KRON News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KRON News Highlights

  • For KRON, its 30 day story count is now at 2.
  • Over the past 14 days, the trend for KRON's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • KB, BIO and DEC are the most mentioned tickers in articles about KRON.

Latest KRON News From Around the Web

Below are the latest news stories about KRONOS BIO INC that investors may wish to consider to help them evaluate KRON as an investment opportunity.

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New development candidate KB-9558 inhibits the KAT domain of p300 and thereby modulates IRF4, a key driver of multiple myeloma; IND-enabling studies underway for expected completion in Q4 2024 Kronos Bio’s first development candidate, KB-0742, cleared 80 mg dose in dose escalation portion of the phase 1/2 trial;

Yahoo | December 18, 2023

Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN mapping will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December

Yahoo | December 4, 2023

Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Norbert Bischofberger, Ph.D., president and chief executive officer, Jorge DiMartino M.D., Ph.D., chief medical officer and executive vice president of clinical development, and Charles Lin, Ph.D., senior vice president of TRN Mapping will participate in a fireside chat at the 35th Annual Piper S

Yahoo | November 27, 2023

Kronos Bio Up 47%, Insider Buyers Are Up 31%

Kronos Bio, Inc. ( NASDAQ:KRON ) insiders who purchased shares in the last 12 months were richly rewarded last week...

Yahoo | November 20, 2023

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates

Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -5.88% and 63.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 13, 2023

Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results

Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences Optimization of resource allocation, restructuring and cost containment extends runway into 2026 Company on track to provide an update on KB-0742 escalation and expansion data as well as lanraplenib expansion cohort data in mid-2024 $198.4 million in cash, cash equivalents and investments as of September 30, 2023 SAN MATEO, Calif., and CAMBRIDGE,

Yahoo | November 13, 2023

Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study

Strategic resource allocation to fully explore KB-0742’s potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study Restructuring plan extends anticipated cash runway into 2026 Company to continue with lanraplenib development and to focus discovery efforts on maturing projects and Genentech collaboration activities SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated

Yahoo | November 2, 2023

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studies at leading international sarcoma meeting KB-0742 demonstrated on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients with transcriptionally addicted solid tumors SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kronos

Yahoo | November 2, 2023

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Ti

Yahoo | October 27, 2023

Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose proportional exposure, dose-dependent target engagement, and 24-hour plasma half-life Dose escalation continues; dosing of patients at the 80 mg dose level is ongoing Enrollment ongoing in dose expansion phase in MYC-dependent and other transcriptionally addicted solid tumors, including lung,

Yahoo | October 13, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!